

# Ultra-Early and Short-Term Tranexamic Acid Treatment in Patients With Good- and Poor-Grade Aneurysmal Subarachnoid Hemorrhage

Maud A. Tjerkstra, MD, René Post, MD, PhD, Menno R. Germans, MD, PhD, Mervyn D.I. Vergouwen, MD, PhD, Korne Jellema, MD, PhD, Radboud W. Koot, MD, PhD, Nyika D. Kruij, MD, PhD, Jasper F.C. Wolfs, MD, PhD, Frits C. De Beer, MD, Hans H. Kieft, MD, PhD, Dharmin Nanda, MD, PhD, Bram Van Der Pol, MD, PhD, Gerwin Roks, MD, PhD, Frank De Beer, MD, Loes J.A. Reichman, MD, Paul J.A.M. Brouwers, MD, PhD, Vincent I.H. Kwa, MD, PhD, Taco C. Van Der Ree, MD, PhD, Henri P. Bienfait, MD, PhD, Hieronymus D. Boogaarts, MD, PhD, Catharina J. Klijn, MD, PhD, Victoria Visser, MD, René van den Berg, MD, PhD, Bert A. Coert, MD, PhD, Janneke Horn, MD, PhD, Charles B.L.M. Majoie, MD, PhD, Gabriël J.E. Rinkel, MD, PhD, Yvo B.W.E.M. Roos, MD, PhD, W. Peter Vandertop, MD, PhD, and Dagmar Verbaan, PhD, on behalf of the ULTRA trial study group

## Correspondence

Dr. Tjerkstra  
m.a.tjerkstra@  
amsterdamumc.nl

*Neurology*® 2024;102:e209169. doi:10.1212/WNL.0000000000209169

## Abstract

### Background and Objectives

The results of the ULTRA trial showed that ultra-early and short-term treatment with tranexamic acid (TXA) does not improve clinical outcome after aneurysmal subarachnoid hemorrhage (aSAH). Possibly, the lack of a beneficial effect in all patients with aSAH is masked by antagonistic effects of TXA in certain subgroups. In this post hoc subgroup analysis, we investigated the effect of TXA on clinical outcome in patients with good-grade and poor-grade aSAH.

### Methods

The ULTRA trial was a multicenter, prospective, randomized, controlled, open-label trial with blinded outcome assessment. Participants received ultra-early and short-term TXA in addition to usual care or usual care only. This post hoc subgroup analysis included only ULTRA participants with confirmed aSAH and available World Federation of Neurosurgical Societies (WFNS) grade on admission. Patients were categorized into those with good-grade (WFNS 1–3) and poor-grade (WFNS 4–5) aSAH. The primary outcome was clinical outcome assessed by the modified Rankin scale (mRS). Odds ratios (ORs) and adjusted ORs (aORs) with 95% CIs were calculated using ordinal regression analyses. Analyses were performed using the as-treated principle. In all patients with aSAH, no significant effect modification of TXA on clinical outcome was observed for admission WFNS grade ( $p = 0.10$ ).

### Results

Of the 812 ULTRA participants, 473 patients had (58%;  $N = 232$  TXA,  $N = 241$  usual care) good-grade and 339 (42%;  $N = 162$  TXA,  $N = 176$  usual care) patients had poor-grade aSAH. In patients with good-grade aSAH, the TXA group had worse clinical outcomes (OR: 0.67, 95% CI 0.48–0.94, aOR 0.68, 95% CI 0.48–0.94) compared with the usual care group. In patients with poor-grade aSAH, clinical outcomes were comparable between treatment groups (OR: 1.04, 95% CI 0.70–1.55, aOR 1.05, 95% CI 0.70–1.56).

From the Department of Neurosurgery (M.A.T., R.P., V.V., B.A.C., W.P.V., D.V.), Amsterdam UMC, University of Amsterdam; Department of Neurosurgery (M.R.G.), Clinical Neuroscience Centre, University Hospital Zurich, Switzerland; Department of Neurology and Neurosurgery (M.D.I.V., G.J.E.R.), UMC Utrecht Brain Centre, University Medical Centre Utrecht; Departments of Neurology (K.J.) and Neurosurgery (J.F.C.W.), Haaglanden Medical Centre, Den Haag; Departments of Neurosurgery (R.W.K.) and Neurology (N.D.K.), Leiden University Medical Centre; Departments of Neurosurgery (F.C.B., D.N.) and Intensive Care (H.K.), ISALA Hospital, Zwolle; Departments of Neurosurgery (B.P.) and Neurology (G.R.), Elisabeth Tweesteden Ziekenhuis, Tilburg; Department of Neurology (F.B.), Spaarne Gasthuis, Haarlem; Department of Neurology (L.J.A.R.), Ziekenhuisgroep Twente, Almelo; Department of Neurology (P.J.A.M.B.), Medisch Spectrum Twente, Enschede; Department of Neurology (V.I.H.K.), OLVG, Amsterdam; Department of Neurology (T.C.R.), Dijklander Hospital, Hoorn; Department of Neurology (H.P.B.), Gelre Hospital, Apeldoorn; Department of Neurosurgery (H.D.B.); Department of Neurology, Donders Institute for Brain, Cognition and Behaviour (C.J.M.K.), Radboud University Medical Centre, Nijmegen; Departments of Radiology and Nuclear Medicine (R.B., C.B.L.M.M.), Intensive Care (J.H.), and Neurology (Y.B.W.E.M.R.), Amsterdam UMC, University of Amsterdam., the Netherlands.


Go to [Neurology.org/N](https://www.neurology.org/N) for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

The Article Processing Charge was funded by the authors.


ULTRA trial study group convestigators are listed at [Neurology.org](https://www.neurology.org).

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

## RELATED ARTICLE

 **Editorial**  
Making Antifibrinolytics  
After Subarachnoid  
Hemorrhage Obsolete  
With Better Care  
Page e209327

## MORE ONLINE

 **Class of Evidence**  
Criteria for rating  
therapeutic and diagnostic  
studies  
[NPub.org/coe](https://www.neurology.org/COE)

## Glossary

aOR = adjusted OR; aSAH = aneurysmal subarachnoid hemorrhage; IQR = interquartile range; mRS = modified Rankin scale; OR = odds ratio; TXA = tranexamic acid; WFNS = World Federation of Neurosurgical Societies.

## Discussion

This post hoc subgroup analysis provides another important argument against the use of TXA treatment in patients with aSAH, by showing worse clinical outcomes in patients with good-grade aSAH treated with TXA and no clinical benefit of TXA in patients with poor-grade aSAH, compared with patients treated with usual care.

## Trial Registration Information

ClinicalTrials.gov (NCT02684812; submission date February 18, 2016, first patient enrollment on July 24, 2013).

## Classification of Evidence

This study provides Class II evidence that tranexamic acid, given for <24 hours within the first 24 hours, does not improve the 6-month outcome in good-grade or poor initial-grade aneurysmal SAH.

## Introduction

Aneurysmal subarachnoid hemorrhage (aSAH) is a devastating disease with high morbidity and mortality. The occurrence of rebleeding is one of the most important factors associated with poor outcome.<sup>1</sup> Risk factors of rebleeding include poor neurologic condition on admission, large aneurysm size, and elevated systolic blood pressure.<sup>1,2</sup> In the past, antifibrinolytics have been shown to decrease the occurrence of rebleeding; however, a positive effect on clinical outcome could not be established.<sup>3,4</sup> The ULTRA trial investigated ultra-early and short-term tranexamic acid (TXA) administration after SAH. The trial was designed to end the decade-long debate on the efficacy of antifibrinolytics on clinical outcome after SAH. The recently published results of the ULTRA trial showed no clinical benefit of TXA after 6 months.<sup>5,6</sup> Moreover, patients in the TXA group less often had excellent clinical outcome compared with those in the usual care group. This has led to significant alterations in international guidelines on the management of SAH, which now advise against the routine use of TXA.<sup>7,8</sup>

Hypothetically, the lack of overall effect of TXA in all patients with SAH may be explained by different effects of TXA in certain subgroups, for example, patients with good and poor neurologic condition on admission. Early brain injury is defined as the initial injury in the first 72 hours after aSAH.<sup>9,10</sup> The pathophysiology of early brain injury includes the formation of microthrombi. Theoretically, reduced degradation of microthrombi by TXA may delay or hinder recovery of early brain injury and, thereby, might have a negative effect on clinical outcome. Because patients with poor-grade aSAH have more severe early brain injury, especially these patients may be negatively influenced by administration of TXA. Because the detrimental impact of rebleedings in patients with good-grade aSAH is generally much larger than in patients who are already in a poor condition, one may expect a beneficial effect of TXA

on clinical outcome in good-grade patients. Therefore, the primary research question in this post hoc subgroup analysis of the ULTRA trial is as follows: does ultra-early and short-term TXA treatment improve clinical outcome at 6 months in patients with good-grade and poor-grade aSAH?

## Methods


### Standard Protocol Approvals, Registrations, and Patient Consents

The study protocol of the ULTRA trial has been previously published.<sup>11,12</sup> In brief, the ULTRA trial was a randomized, controlled, multicenter, open-label trial with blinded outcome assessment. The trial was conducted in 8 treatment centers and 16 referral hospitals between July 24, 2013, and January 20, 2020. The study was performed in accordance with the principles of the Declaration of Helsinki and International Conference of Harmonization guidelines for Good Clinical Practice and was registered on ClinicalTrials.gov (NCT02684812). The ethics committee of the Amsterdam University Medical Center (Amsterdam UMC, Amsterdam, the Netherlands) approved the trial protocol (2012\_160#2012370). A description of the informed consent procedure has been previously published.<sup>11,12</sup>

### Patients and Intervention

For this post hoc study of the ULTRA trial (NCT02684812), we excluded ULTRA participants without confirmed causative intracranial aneurysm on CT angiography and/or digital subtraction angiography. Patients were allocated (1:1 randomization, stratified by treatment center) to either ultra-early (immediately after SAH diagnosis and within 24 hours of ictus) and short-term (until aneurysm treatment or maximally 24 hours) TXA in addition to usual care or usual care only.<sup>11</sup> Patients, investigators, and health care providers were not masked to study drug assignment. For the purpose of this study, patients were categorized into patients with good-grade (WFNS I-III) and poor-grade (WFNS IV-V) aSAH

**Figure 1** Flow Diagram of Included Patients



based on the WFNS grade. The WFNS grade was scored based on the Glasgow coma scale score and presence or absence of motor impairment on admission at the referral hospital or, in case of immediate presentation at the treatment center, at the treatment center. Patients of whom the WFNS grade classification was unavailable due to an incomplete neurologic assessment on admission were excluded.

### Data Collection

We used prospectively collected baseline characteristics: age, sex, medication use (platelet inhibitors, anticoagulation, and antihypertensive drugs), WFNS grade<sup>10</sup> on admission, Fisher grade<sup>13</sup> on first noncontrast head CT, and aneurysm location. Other collected data included the following: treatment modality (endovascular, clipping, and none); information on timing of TXA administration and aneurysm treatment; and the occurrence of common complications following aSAH: rebleeding (CT-proven and all rebleedings), hydrocephalus, delayed cerebral ischemia, thromboembolic complications during endovascular treatment, cerebral infarction related to clipping procedure, per-procedural rupture, extracranial thrombosis, hemorrhagic complications, severe hyponatremia, pneumonia, infectious

meningitis, urinary tract infection, seizures, delirium, and the mRS score and mortality at 6 months after aSAH (eMethods, page 1–2).<sup>5,6</sup>

### Outcomes

The primary outcome was the mRS score, ranging from 0 (no symptoms) to 6 (death), at 6 months after aSAH. Secondary outcomes included good (mRS 0–3) and excellent (mRS 0–2) clinical outcomes 6 months after aSAH, all-cause mortality at 30 days and 6 months after aSAH, and the aforementioned complications following aSAH.

### Statistical Analysis

All analyses were performed for patients with good-grade (WFNS I–III) and poor-grade (WFNS IV–V) aSAH separately. Because the selection of subgroups undoes the randomization, we deemed it more informative and methodologically robust to use the as-treated principle. Patients who actually received TXA treatment in addition to usual care were assigned to the “TXA group” and patients who received usual care only were assigned to the “usual care group.” Hereby, we aimed to provide a more accurate representation of the impact of TXA on clinical

**Table 1** Baseline Characteristics of Patients With Good-Grade and Poor-Grade aSAH According to the As-Treated Principle

	Good-grade aSAH WFNS I-III (N = 473)			Poor-grade aSAH WFNS IV-V (N = 338)		
	TXA group (N = 232)	Usual care group (N = 241)	<i>p</i> Value	TXA group (N = 162)	Usual care group (N = 176)	<i>p</i> Value
Age, mean (SD)	58 (13)	58 (13)	0.79	59 (13)	59 (12)	0.77
Female	163 (70)	169 (70)	1.00	122 (75)	122 (69)	0.23
Fisher grade			0.44			0.16
II	20 (9)	14 (6)		1 (1)	1 (1)	
III	79 (34)	90 (37)		19 (12)	34 (19)	
IV	135 (57)	137 (57)		142 (88)	141 (80)	
Medication use						
Platelet inhibitor	24 (10)	24 (10)	0.88	24 (15)	25 (14)	0.88
Anticoagulation	8 (4)	7 (3)	0.80	5 (3)	7 (4)	0.77
Antihypertensive drugs	58 (25)	54 (22)	0.52	36 (23)	40 (23)	1.00
None of the above	156 (68)	170 (71)	0.49	112 (70)	118 (67)	0.64
Location of aneurysm			0.24			0.41
Anterior circulation	183 (79)	202 (84)		134 (83)	139 (79)	
Posterior circulation	48 (21)	39 (16)		28 (17)	37 (21)	
Treatment modality			0.79			0.55
Endovascular	166 (72)	168 (70)		98 (61)	97 (55)	
Clipping	50 (22)	58 (24)		30 (19)	36 (21)	
None	16 (7)	15 (6)		33 (21)	43 (24)	

Data presented as n (%), unless noted otherwise. Percentages may not total 100 because of rounding. The as-treated analyses included 811 patients (n = 1 patient of whom it was unknown whether TXA was administered or not). Missing data in patients with good grade aSAH: medication use, N = 1 missing. Missing data in patients with poor-grade aSAH: medication use, N = 3 missing; location of aneurysm, N = 1 missing; and treatment modality, N = 1 missing.

outcome in patients with good-grade and poor-grade aSAH. Normality of continuous data was tested using the Shapiro-Wilk test (statistic test threshold of 0.9). Baseline characteristics were compared between the TXA group and usual care group using the Chi-Square test, independent sample *t* test, Fisher exact test, or Mann-Whitney *U* test, depending on the distribution of the data. The primary outcome was analyzed using ordinal regression analysis. Secondary outcomes were analyzed using logistic regression analyses. Odds ratios (ORs) with corresponding 95% confidence interval (CIs) were calculated. For the primary outcome, good clinical outcome, excellent clinical outcome, and mortality at 30 days and 6 months, adjusted ORs (aOR) with 95% CIs were calculated adjusting for treatment center and for baseline characteristics with a *p* value <0.2. Effect modification of TXA by admission WFNS grade was tested using ordinal regression analyses with clinical outcome as dependent variable and as-treated treatment group (TXA or usual care), admission WFNS grade, and an interaction term (as-treated treatment group \* admission WFNS grade) as independent variables, using all patients with aSAH. If the calculated *p* value of the interaction term was <0.05, effect modification was considered significant. Analyses

were also performed in patient groups according to the intention-to-treat principle, in which patients were analyzed according to the group they were allocated to by randomization. Missing data were handled using a pairwise deletion method, in which incomplete cases were deleted on an analysis-by-analysis basis, and frequencies were calculated using the total number of patients with available data. Statistical analyses were performed using the IBM SPSS Statistics version 28 software (IBM Corporation, Armonk, NY).

### Data Availability


The authors have reported all relevant data used to conduct the research. All data requests should be submitted to the Principal Investigator (DV) for consideration. Access to anonymized data may be granted following review.

## Results

### Patients

The ULTRA trial enrolled 955 participants, of whom 813 had aSAH. One patient with Glasgow coma scale score 13 could

**Figure 2** Distribution of Modified Rankin Scale Score at 6 Months in Both Treatment Groups, Separately Analyzed for Patients With Good-Grade and Poor-Grade aSAH, Using the As-Treated Principle



Stacked bar chart of scores on the modified Rankin scale (0–6). A score of 0 indicates no symptoms, 1 no clinically significant disability, 2 slight disability (patient is able to look after own affairs without assistance, but is unable to perform all previous activities), 3 moderate disability (patient requires some help but is able to walk unassisted), 4 moderately severe disability (patient is unable to attend to bodily needs without assistance and unable to walk unassisted), 5 severe disability (patient requires constant nursing care and attention), and 6 death. In good-grade patients, the overall distribution of the mRS scores 6 months after aSAH with ordinal regression analysis differed significantly between the TXA and usual care groups, showing worse mRS scores in the TXA group (OR 0.67, 95% CI 0.48–0.94; aOR 0.68, 95% CI 0.48–0.94, adjusted for treatment center). In poor-grade patients, the overall distribution of mRS scores 6 months after aSAH with ordinal regression analysis showed no significant differences between the TXA and usual care groups, OR 1.04, 95% CI 0.70–1.55, neither after adjustment for treatment center, aOR 1.05, 95% CI 0.70–1.56. aSAH = aneurysmal subarachnoid hemorrhage; mRS = modified Rankin scale; TXA = tranexamic acid.

not be classified into good-grade or poor-grade aSAH due to missing information about focal neurologic impairment and was therefore excluded from this analysis. The remaining 812 patients were classified into those with good-grade (N = 473, 58%) or poor-grade (N = 339, 42%) aSAH. The mRS score at follow-up was available in 803 (99%) patients (Figure 1).

### Intervention

In 1 patient, allocated to the TXA group, it was uncertain whether TXA was administered, and this patient was therefore excluded from the as-treated analysis. Of patients with good-grade aSAH, 232 (49%) received TXA treatment in addition to usual care and 241 (51%) received usual care only. TXA treatment was administered within a median of 78 (interquartile range [IQR] 50–139) minutes after confirmation of SAH. Aneurysm treatment was performed within a median of 15 (IQR 7–20) hours after SAH diagnosis. Of patients with poor-grade aSAH, 162 (48%) received TXA treatment in addition to usual care and 176 (52%) received usual care only. TXA treatment was administered at a median of 70 (IQR 47–124) minutes after confirmation of SAH. Aneurysm treatment was performed at a median of 12 (IQR 4–23) hours after SAH diagnosis. Baseline characteristics did not differ between treatment groups in patients with good-grade and poor-grade aSAH (Table 1). In the intention-to-treat analyses of baseline characteristics, only Fisher grade significantly differ between both treatment groups (eTable 1).

### Outcomes

#### Patients With Good-Grade aSAH

The mRS score at 6 months after aSAH was available for 468 of 473 (99%) patients with good-grade aSAH. The overall

distribution of mRS scores at 6 months showed that patients in the TXA group had worse clinical outcome than patients in the usual care group (OR 0.67, 95% CI 0.48–0.94; aOR, adjusted for treatment center, 0.68, 95% CI 0.48–0.94 (Figure 2). None of the baseline characteristics had a *p* value <0.20; therefore, no adjustment was made for baseline characteristics. Patients in the TXA group less often had excellent clinical outcome than patients in the usual care group (133/232, 58% vs 161/241, 67%; aOR, adjusted for treatment center, 0.67, 95% CI 0.46–0.97; Table 2). Other secondary outcomes and the occurrence of rebleeding and ischemic/thrombotic complications did not differ significantly between treatment groups (Tables 2 and 3). Hydrocephalus more frequently occurred in the TXA group (138/232, 60%) than in the usual care group (121/241, 50%), OR 1.46, 95% CI 1.01–2.10. The frequency of interventions for hydrocephalus, including lumbar puncture, external lumbar drainage, external ventricular drainage, and permanent ventriculoperitoneal shunting, did not significantly differ between the treatment groups (eTable 2).

In the intention-to-treat analyses, the OR for hydrocephalus was not statistically significant (OR 1.38, 95% CI 0.97–2.00). Other results were similar to the as-treated analyses (eTable 3–4 and eFigure 1).

#### Patients With Poor-Grade aSAH

The mRS score at 6 months after aSAH was obtained for 334 of 339 (99%) patients with poor-grade aSAH. The overall distribution of mRS scores at 6 months showed no significant differences between the TXA and usual care groups (OR: 1.04, 95% CI 0.70–1.55; aOR, adjusted for treatment center: 1.05, 95% CI 0.70–1.56; Figure 2). None of the baseline characteristics had a

**Table 2** Primary and Secondary Outcomes for Patients With Good-Grade and Poor-Grade aSAH According to the As-Treated Principle

	Good-grade aSAH WFNS I-III (N = 473)			Poor-grade aSAH WFNS IV-V (N = 338)		
	TXA group (N = 232)	Usual care group (N = 241)	OR (95% CI) aOR (95% CI)	TXA group (N = 162)	Usual care group (N = 176)	OR (95% CI) aOR (95% CI)
<b>Primary outcome</b>						
<b>mRS scores at 6 mo<sup>a</sup></b>			0.67 (0.48–0.94) 0.68 (0.48–0.94)			1.04 (0.70–1.55) 1.05 (0.70–1.56)
<b>mRS 0</b>	10 (4)	13 (6)		3 (2)	3 (2)	
<b>mRS 1</b>	19 (8)	38 (16)		6 (4)	3 (2)	
<b>mRS 2</b>	104 (45)	110 (46)		35 (22)	42 (24)	
<b>mRS 3</b>	34 (15)	18 (8)		16 (10)	17 (10)	
<b>mRS 4</b>	11 (5)	9 (4)		11 (7)	7 (4)	
<b>mRS 5</b>	13 (6)	21 (9)		18 (11)	19 (11)	
<b>mRS 6</b>	38 (17)	30 (13)		72 (45)	82 (47)	
<b>Secondary outcomes</b>						
<b>Good clinical outcome<sup>a</sup></b>	167 (73)	179 (75)	0.90 (0.60–1.36) 0.90 (0.60–1.36)	60 (37)	65 (38)	0.99 (0.63–1.54) 0.98 (0.63–1.56)
<b>Excellent clinical outcome<sup>a</sup></b>	133 (58)	161 (67)	0.67 (0.46–0.98) 0.67 (0.46–0.97)	44 (27)	48 (28)	0.98 (0.61–1.58) 0.97 (0.59–1.59)
<b>All-cause mortality at 30 d</b>	30 (13)	27 (11)	1.18 (0.68–2.05) 1.18 (0.67–2.07)	62 (38)	72 (41)	0.90 (0.58–1.39) 0.92 (0.59–1.44)
<b>All-cause mortality at 6 mo</b>	38 (16)	30 (12)	1.38 (0.82–2.31) 1.39 (0.82–2.34)	72 (44)	82 (47)	0.92 (0.60–1.41) 0.93 (0.60–1.44)

Data presented as n (%), unless noted otherwise. Percentages may not total 100 because of rounding. Odds ratio (OR), adjusted odds ratio (aOR; adjusted for treatment center in both good-grade and poor-grade patients), 95% confidence interval (95% CI). The as-treated analyses included 811 patients (n = 1 patient of whom it was unknown whether TXA was administered or not).

<sup>a</sup> In good-grade aSAH group: N = 5 patients lost to follow-up (N = 229 in the TXA group and N = 239 in the usual care group). In poor-grade aSAH group: N = 4 patients lost to follow-up (N = 161 in the TXA group and N = 173 in the usual care group).

*p* value <0.20; therefore, no adjustment was made for baseline characteristics. Secondary outcomes also did not differ significantly (Table 2). Patients in the TXA group more frequently had seizures than patients in the usual care group (28/162, 17% vs 17/176, 10%; OR 1.95, 95% CI 1.03–3.73; Table 3). The occurrence of rebleeding, ischemic/thrombotic, and all other complications were not different between treatment groups. The intention-to-treat analyses showed similar results as the as-treated analyses (eTables 3–4 and eFigure 1). In all patients with aSAH, no significant effect modification of TXA on clinical outcome was observed for admission WFNS grade (*p* = 0.10).

## Discussion

This post hoc study shows worse clinical outcome in patients with good-grade aSAH treated with TXA and no clinical benefit of TXA treatment in patients with poor-grade aSAH, compared with patients treated with usual care. The recently published results of the ULTRA trial have further elucidated the decade-

long debate on the efficacy of antifibrinolytics on clinical outcome after aSAH by showing no clinical benefit of ultra-early and short-term TXA treatment. Possibly, an overall effect was masked by different effects in certain subgroups of patients. We hypothesized a harmful effect of TXA in patients with poor-grade aSAH and a beneficial effect of TXA in patients with good-grade aSAH. However, the results of our post hoc subgroup analyses show the contrary: TXA seems to be harmful in patients with good-grade aSAH, based on worse mRS scores and less excellent clinical outcome in patients treated with TXA compared with patients treated with usual care. This could not be explained by differences in the occurrence of rebleeding or ischemic/thromboembolic complications. In patients with poor-grade aSAH, clinical outcome did not differ significantly between treatment groups.

Evaluation of common complications following aSAH in patients with good-grade aSAH revealed a higher occurrence of hydrocephalus in the TXA group. The mechanism of action of TXA is to prevent rebleeding by reducing blood clot breakdown. Hypothetically, a reduction of blood clot breakdown in

**Table 3** Frequency of Adverse Events of Patients With Good-Grade and Poor-Grade aSAH According to the As-Treated Principle

	Good-grade aSAH WFNS I-III (N = 473)			Poor-grade aSAH WFNS IV-V (N = 338)		
	TXA group (N = 232)	Usual care group (N = 241)	OR (95% CI)	TXA group (N = 162)	Usual care group (N = 176)	OR (95% CI)
<b>All rebleedings before aneurysm treatment</b>	24 (10)	31 (13)	0.78 (0.44–1.38)	22 (14)	34 (19)	0.66 (0.37–1.18)
<b>CT-proven rebleedings before aneurysm treatment</b>	23 (10)	29 (12)	0.80 (0.45–1.44)	15 (9)	28 (16)	0.54 (0.28–1.05)
<b>Hydrocephalus</b>	138 (60)	121 (50)	1.46 (1.01–2.10)	112 (69)	126 (72)	0.89 (0.56–1.42)
<b>Delayed cerebral ischemia</b>	60 (26)	60 (25)	1.05 (0.70–1.59)	38 (24)	48 (27)	0.81 (0.50–1.33)
<b>Thromboembolic complications during endovascular treatment</b>	18 (11)	24 (14)	0.73 (0.38–1.40)	11 (11)	9 (9)	1.24 (0.49–3.13)
<b>Cerebral infarction related to clipping procedure</b>	14 (28)	9 (16)	2.12 (0.83–5.43)	8 (27)	9 (14)	1.05 (0.35–3.18)
<b>Per-procedural rupture</b>						
<b>Coiling</b>	8 (5)	7 (4)	1.17 (0.41–3.29)	7 (7)	6 (6)	1.17 (0.38–3.61)
<b>Clipping</b>	9 (18)	15 (26)	0.63 (0.25–1.60)	7 (23)	8 (22)	1.07 (0.34–3.38)
<b>Extracranial thrombosis<sup>a</sup></b>	3 (1)	1 (0)	3.14 (0.33–30.5)	2 (1)	6 (3)	0.35 (0.70–1.78)
<b>Hemorrhagic complication</b>	14 (6)	18 (8)	0.80 (0.39–1.64)	12 (8)	16 (9)	0.81 (0.37–1.76)
<b>Severe hyponatraemia</b>	7 (3)	7 (3)	1.04 (0.36–3.01)	4 (3)	1 (1)	4.43 (0.49–40.1)
<b>Pneumonia</b>	19 (8)	30 (12)	0.63 (0.34–1.15)	32 (20)	38 (22)	0.89 (0.53–1.52)
<b>Infectious meningitis</b>	18 (8)	19 (8)	0.98 (0.50–1.92)	9 (6)	13 (7)	0.74 (0.31–1.78)
<b>Urinary tract infection</b>	21 (9)	33 (14)	0.63 (0.35–1.12)	15 (9)	9 (5)	1.89 (0.81–4.46)
<b>Seizure</b>	24 (10)	24 (10)	1.04 (0.57–1.90)	28 (17)	17 (10)	1.95 (1.03–3.73)
<b>Delirium</b>	31 (13)	33 (14)	0.97 (0.57–1.65)	23 (14)	23 (13)	1.10 (0.59–2.05)

Data presented as n (%), unless noted otherwise. Odds ratio (OR), adjusted odds ratio (aOR), 95% confidence interval (95% CI). The as-treated analyses included 811 patients (n = 1 patient of whom it was unknown whether TXA was administered or not).

Missing data in poor grade aSAH: delayed cerebral ischemia, N = 1 missing, cerebral infarction related to clipping procedure, N = 1 missing, and hemorrhagic complication, N = 1 missing.

<sup>a</sup> Extracranial thrombosis includes deep venous thrombosis and pulmonary embolism.

the subarachnoid space may impede absorption of the CSF and, as a consequence, may lead to hydrocephalus. In 2022, a systematic review with meta-analyses, including the ULTRA trial and 6 other randomized controlled trials, showed a significantly 13% higher pooled incidence of hydrocephalus in patients with SAH treated with TXA compared with that in controls.<sup>14</sup> On the contrary, a 2022 Cochrane review, including the ULTRA trial and 5 other randomized controlled trials, showed a RR of 1.09, 95% CI 0.9 to 1.20 for hydrocephalus in patients treated with antifibrinolytic treatment vs controls.<sup>4</sup> Whether the observed higher occurrence of hydrocephalus in patients with good-grade aSAH using TXA is clinically relevant cannot be concluded based on our results. In patients with poor-grade aSAH, the incidence of hydrocephalus is known to be high already (in ULTRA participants with aSAH: 64% in the TXA group and 59% in the usual care group<sup>6</sup>; in patients with poor-grade aSAH: 69% in the TXA and 72% in the usual care

group). The relatively high incidence of hydrocephalus in patients with poor-grade aSAH could mask an additional harmful effect of tranexamic acid.

A higher occurrence of seizures was observed in patients with poor-grade aSAH treated with TXA compared with those treated with usual care. Seizures following TXA administration have been repeatedly reported in studies on cardiac surgery and after accidental high-dose intrathecal TXA injections.<sup>15</sup> This phenomenon has previously been explained by the structural similarity of TXA and both glycine and GABA receptors.<sup>16</sup> Possibly, the seizure-inducing effect of TXA may be more pronounced in patients with poor-grade aSAH because the blood-brain barrier is often disturbed in these patients. Because poor-grade patients are associated with more early brain injury, they may therefore be more prone to TXA-induced seizures than patients with good-grade aSAH.

Strengths of this study are the large sample size, nationwide participation, blinded outcome assessment, and the negligible number of patients who were lost to follow-up. Our study has several limitations. Because this study is a post hoc analysis, it may be underpowered for the addressed research questions. Only a selection of ULTRA participants was used, which could lead to differences between treatment groups. However, baseline characteristics were evenly distributed among the treatment groups. The Netherlands is a very small and densely populated country, resulting in a relatively small time interval between aSAH ictus and aneurysm obliteration. Other countries may have larger ictus to aneurysm treatment time intervals with a subsequent higher risk of rebleeding. Therefore, this study may lack generalizability. Last, treatment and safety outcomes were not blinded.

This post hoc subgroup analysis provides another important argument against the use of TXA in patients with aSAH, by showing worse clinical outcomes in patients with good-grade aSAH treated with TXA and no clinical benefit of TXA treatment in patients with poor-grade aSAH, compared with patients treated with usual care. The use of TXA may potentially lead to more frequent hydrocephalus in patients with good-grade aSAH and seizures in patients with poor-grade aSAH support our admonition.

### Acknowledgment

Foremost, the authors thank the patients participating in this trial, without whom this trial would have not been possible. The authors also thank the research teams in all participating centers who contributed to the data collection.

### Study Funding

The ULTRA trial was funded by the Fonds NutsOhra (project 1202-31). The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the manuscript.

### Disclosure

All authors have completed the ICMJE uniform disclosure form at [www.icmje.org/coi\\_disclosure.pdf](http://www.icmje.org/coi_disclosure.pdf) and declare: M.D.I. Vergouwen reports a grant from the Dutch Heart Foundation (Clinical Established Investigator grant 2018T076); J.F.C. Wolfs reports personal fees from Consultant Nuvasive, personal fees from Zimmer Biomet, personal fees from Safe Orthopaedics, and personal fees from EIT/Johnson and Johnson, outside the submitted work; H.D. Boogaarts reports consulting fees paid to the Department of Neurosurgery, Radboud University Medical Center Nijmegen from Stryker neurovascular; R. van den Berg reports consulting fees for unrelated research and teaching activities from Cerenovus Neurovascular; C.B.L.M. Majoie reports grants from CVON/Dutch Heart Foundation, grants from European Commission, grants from Dutch Health Evaluation Program, grants from TWIN Foundation, and grants from Stryker, outside the submitted work and is a Shareholder of Nico-Lab, a company that focuses on the use of artificial

intelligence for medical image analysis; G.J.E. Rinkel reports no disclosures relevant to the manuscript; Y.B.W.E.M. Roos is a minor stockholder of Nico-Lab; D. Verbaan reports funding of Fonds NutsOhra; the other authors report no relevant disclosures. Go to [Neurology.org/N](http://Neurology.org/N) for full disclosures.

### Publication History

Received by *Neurology* June 23, 2023. Accepted in final form January 9, 2024. Submitted and externally peer reviewed. The handling editor was Editor-in-Chief José Merino, MD, MPhil, FAAN.

### Appendix 1 Authors

Name	Location	Contribution
<b>Maud A. Tjerckstra, MD</b>	Department of Neurosurgery, Amsterdam UMC, University of Amsterdam	Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data; and analysis or interpretation of data
<b>René Post, MD, PhD</b>	Department of Neurosurgery, Amsterdam UMC, University of Amsterdam	Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data; study concept or design; and analysis or interpretation of data
<b>Menno R. Germans, MD, PhD</b>	Department of Neurosurgery, Clinical Neuroscience Centre, University Hospital Zurich	Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data; and study concept or design
<b>Mervyn D.I. Vergouwen, MD, PhD</b>	Department of Neurology and Neurosurgery, UMC Utrecht Brain Centre, University Medical Centre Utrecht	Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data
<b>Korne Jellema, MD, PhD</b>	Department of Neurology, Haaglanden Medical Centre	Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data
<b>Radboud W. Koot, MD, PhD</b>	Department of Neurosurgery, Leids University Medical Centre	Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data
<b>Nyika D. Kruyt, MD, PhD</b>	Department of Neurology, Leids University Medical Centre	Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data
<b>Jasper F.C. Wolfs, MD, PhD</b>	Department of Neurosurgery, Haaglanden Medical Centre	Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data
<b>Frits C. De Beer, MD</b>	Department of Neurosurgery, ISALA Hospital	Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data



**Appendix 1** (continued)

Name	Location	Contribution
<b>Hans Kieft, MD, PhD</b>	Department of Intensive Care, ISALA Hospital	Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data
<b>Dharmin Nanda, MD, PhD</b>	Department of Neurosurgery, ISALA Hospital	Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data
<b>Bram Van Der Pol, MD, PhD</b>	Department of Neurosurgery, Elisabeth Tweesteden Ziekenhuis	Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data
<b>Gerwin Roks, PhD</b>	Department of Neurology, Elisabeth Tweesteden Ziekenhuis	Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data
<b>Frank De Beer, MD</b>	Department of Neurology, Spaarne Gasthuis	Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data
<b>Loes J. Reichman, MD</b>	Department of Neurology, Ziekenhuisgroep Twente	Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data
<b>Paul J.A.M. Brouwers, MD, PhD</b>	Department of Neurology, Medisch Spectrum Twente	Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data
<b>Vincent I.H. Kwa, MD, PhD</b>	Department of Neurology, OLVG	Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data
<b>Taco C. Van Der Ree, MD, PhD</b>	Department of Neurology, Dijklander Hospital	Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data
<b>Henri Paul Bienfait, MD, PhD</b>	Department of Neurology, Gelre Hospital	Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data
<b>Hieronymus D. Boogaarts, MD, PhD</b>	Department of Neurosurgery, Radboud University Medical Centre	Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data
<b>Catharina J.M. Klijn, MD, PhD</b>	Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Centre	Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data
<b>Victoria Visser, MD</b>	Department of Neurosurgery, Amsterdam UMC, University of Amsterdam	Drafting/revision of the article for content, including medical writing for content

**Appendix 1** (continued)

Name	Location	Contribution
<b>René van den Berg, MD, PhD</b>	Department of Radiology and Nuclear Medicine, Amsterdam UMC, University of Amsterdam	Drafting/revision of the article for content, including medical writing for content; study concept or design
<b>Bert A. Coert, MD, PhD</b>	Department of Neurosurgery, Amsterdam UMC, University of Amsterdam	Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data; study concept or design; and analysis or interpretation of data
<b>Janneke Horn, MD, PhD</b>	Department of Intensive Care, Amsterdam UMC, University of Amsterdam	Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data; and study concept or design
<b>Charles B.L.M. Majoie, MD, PhD</b>	Department of Radiology and Nuclear Medicine, Amsterdam UMC, University of Amsterdam	Drafting/revision of the article for content, including medical writing for content; study concept or design
<b>Gabriël J.E. Rinkel, MD, PhD</b>	Department of Neurology and Neurosurgery, UMC Utrecht Brain Centre, University Medical Centre Utrecht	Drafting/revision of the article for content, including medical writing for content; study concept or design
<b>Yvo B.W.E.M. Roos, MD, PhD</b>	Department of Neurology, Amsterdam UMC, University of Amsterdam	Drafting/revision of the article for content, including medical writing for content; study concept or design
<b>W. Peter Vandertop, MD, PhD</b>	Department of Neurosurgery, Amsterdam UMC, University of Amsterdam	Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data; study concept or design; and analysis or interpretation of data
<b>Dagmar Verbaan, MD, PhD</b>	Department of Neurosurgery, Amsterdam UMC, University of Amsterdam	Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data; study concept or design; and analysis or interpretation of data

**Appendix 2** Coinvestigators

Coinvestigators are listed at [Neurology.org](https://www.neurology.org).

**References**

- Larsen CC, Astrup J. Rebleeding after aneurysmal subarachnoid hemorrhage: a literature review. *World Neurosurg*. 2013;79(2):307-312. doi:10.1016/j.wneu.2012.06.023
- Guo L-M, Zhou H-Y, Xu J-W, Wang Y, Qiu Y-M, Jiang J-Y. Risk factors related to aneurysmal rebleeding. *World Neurosurg*. 2011;76(3-4):292-298. doi:10.1016/j.wneu.2011.03.025
- Baharoglu MI, Germans MR, Rinkel GJ, et al. Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage. *Cochrane Database Syst Rev*. 2013;2013(8):CD001245. doi:10.1002/14651858.cd001245.pub2
- Germans MR, Dronkers WJ, Baharoglu MI, et al. Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage. *Cochrane Database Syst Rev*. 2022;11(11):CD001245. doi:10.1002/14651858.CD001245.pub3

5. Post R, Germans MR, Tjerkstra MA, et al. Ultra-early tranexamic acid after subarachnoid haemorrhage (ULTRA): a randomised controlled trial. *Lancet (London, England)* 2021;397(10269):112-118. doi:10.1016/S0140-6736(20)32518-6
6. Tjerkstra MA, Post R, Germans MR, et al. Tranexamic acid after aneurysmal subarachnoid hemorrhage: post-hoc analysis of the ULTRA trial. *Neurology*. 2022; 99(23):e2605-e2614. doi:10.1212/WNL.000000000000201160
7. Hoh BL, Ko NU, Amin-Hanjani S, et al. 2023 guideline for the management of patients with aneurysmal subarachnoid hemorrhage: a guideline from the American Heart Association/American Stroke Association. *Stroke*. 2023;54(7):e314-e370. doi:10.1161/STR.0000000000000436
8. Treggiari MM, Rabinstein AA, Busl KM, et al. Guidelines for the neurocritical care management of aneurysmal subarachnoid hemorrhage. *Neurocrit Care*. 2023;39(1):1-28. doi:10.1007/s12028-023-01713-5
9. Rass V, Helbok R. Early brain injury after poor-grade subarachnoid hemorrhage. *Curr Neurol Neurosci Rep*. 2019;19(10):78. doi:10.1007/s11910-019-0990-3
10. Report of World Federation of neurological Surgeons committee on a universal subarachnoid hemorrhage grading scale. *J Neurosurg*. 1988;68:985-986.
11. Germans MR, Post R, Coert BA, Rinkel GJ, Vandertop WP, Verbaan D. Ultra-early tranexamic acid after subarachnoid hemorrhage (ULTRA): study protocol for a randomized controlled trial. *Trials*. 2013;14(1):143. doi:10.1186/1745-6215-14-143
12. Post R, Germans MR, Coert BA, Rinkel GJ, Vandertop WP, Verbaan D. Update of the ULtra-early TRanexamic Acid after Subarachnoid Hemorrhage (ULTRA) trial: statistical analysis plan. *Trials*. 2020;21(1):199. doi:10.1186/s13063-020-4118-5
13. Fisher CM, Kistler JP, Davis JM. Relation of cerebral vasospasm to subarachnoid hemorrhage visualized by computerized tomographic scanning. *Neurosurgery*. 1980; 6(1):1-9. doi:10.1227/00006123-198001000-00001
14. Ren J, Qian D, Wu J, et al. Safety and efficacy of tranexamic acid in aneurysmal subarachnoid hemorrhage: a meta-analysis of randomized controlled trials. systematic review. *Front Neurol*. 2022;12:710495. doi:10.3389/fneur.2021.710495
15. Ng W, Jerath A, Wąsowicz M. Tranexamic acid: a clinical review. *Anaesthesiology Intensive Ther*. 2015;47(4):339-350. doi:10.5603/AIT.a2015.0011
16. de Faria JL, da Silva Brito J, Costa e Silva LT, et al. Tranexamic acid in Neurosurgery: a controversy indication—review. *Neurosurg Rev*. 2021;44(3):1287-1298. doi:10.1007/s10143-020-01324-0